Comparative Pharmacology
Head-to-head clinical analysis: FLUOROURACIL versus PURIXAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUOROURACIL versus PURIXAN.
FLUOROURACIL vs PURIXAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorouracil is a pyrimidine analog that inhibits thymidylate synthase, blocking DNA synthesis. It is metabolized to active nucleotides (FdUMP, FUTP) which incorporate into RNA and inhibit thymidylate synthase, leading to cell cycle arrest and apoptosis.
Purixan (mercaptopurine) is a purine analog that inhibits de novo purine synthesis by interfering with nucleotide interconversion and incorporation into DNA and RNA. It requires intracellular activation to 6-mercaptopurine ribonucleotide (6-MP ribonucleotide) via hypoxanthine-guanine phosphoribosyltransferase (HGPRT).
425 mg/m² IV bolus on days 1-5 every 28 days (Mayo regimen) or 400 mg/m² IV bolus on day 1, then 2400 mg/m² continuous IV infusion over 46 hours (FOLFOX regimen). For topical use, 5% cream applied twice daily for 2-4 weeks.
75 mg/kg once weekly orally; may be increased by 25 mg/kg every 2-4 weeks to a maximum of 150 mg/kg once weekly.
None Documented
None Documented
Clinical Note
moderateFluorouracil + Digoxin
"Fluorouracil may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateFluorouracil + Digitoxin
"Fluorouracil may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateFluorouracil + Deslanoside
"Fluorouracil may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateFluorouracil + Acetyldigitoxin
"Fluorouracil may decrease the cardiotoxic activities of Acetyldigitoxin."
Biphasic: initial α-phase 10-20 min; terminal β-phase 16-20 min (no accumulation). For continuous infusion, functional half-life ~20 min. Clinically, rapid clearance necessitates infusion schedules.
Terminal elimination half-life is approximately 3-4 hours in adults with normal renal function; prolonged to 20-50 hours in renal impairment. Clinically, monitoring for myelosuppression is essential due to accumulation.
Renal: 60-80% as intact drug and metabolites (primarily urea, CO2, α-fluoro-β-alanine). Fecal: <10%. Biliary: minor.
Renal excretion of unchanged drug and metabolites; approximately 50% as unchanged drug, 20% as 6-thiouric acid, and minor amounts as other metabolites. Biliary/fecal elimination accounts for less than 10%.
Category D/X
Category C
Antimetabolite
Antimetabolite